These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28425413)

  • 1. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
    Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
    Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
    Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
    J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
    Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
    Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
    John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
    Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation.
    Montano-Loza AJ; Lytvyak E; Hirschfield G; Hansen BE; Ebadi M; Berney T; Toso C; Magini G; Villamil A; Nevens F; Van den Ende N; Pares A; Ruiz P; Terrabuio D; Trivedi PJ; Abbas N; Donato MF; Yu L; Landis C; Dumortier J; Dyson JK; van der Meer AJ; de Veer R; Pedersen M; Mayo M; Manns MP; Taubert R; Kirchner T; Belli LS; Mazzarelli C; Stirnimann G; Floreani A; Cazzagon N; Russo FP; Burra P; Zigmound U; Houri I; Carbone M; Mulinacci G; Fagiuoli S; Pratt DS; Bonder A; Schiano TD; Haydel B; Lohse A; Schramm C; Rüther D; Casu S; Verhelst X; Beretta-Piccoli BT; Robles M; Mason AL; Corpechot C;
    J Hepatol; 2024 Oct; 81(4):679-689. PubMed ID: 38821360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
    Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Harms MH; de Veer RC; Lammers WJ; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Trivedi PJ; Hirschfield GM; Pares A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Hansen BE; Buuren HRV; van der Meer AJ
    Gut; 2020 Aug; 69(8):1502-1509. PubMed ID: 31843787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
    Cheung AC; Lammers WJ; Murillo Perez CF; van Buuren HR; Gulamhusein A; Trivedi PJ; Lazaridis KN; Ponsioen CY; Floreani A; Hirschfield GM; Corpechot C; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Nevens F; Thorburn D; Mason AL; Carbone M; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lindor KD; Lleo A; Poupon R; Janssen HLA; Hansen BE;
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2076-2084.e2. PubMed ID: 30616022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
    Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
    Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
    Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased infiltration of CD4
    Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
    Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.
    Harms MH; Lammers WJ; Thorburn D; Corpechot C; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Dalekos GN; Bruns T; Parés A; Mason AL; Verhelst X; Kowdley KV; Goet JC; Hirschfield GM; Hansen BE; van Buuren HR;
    Am J Gastroenterol; 2018 Feb; 113(2):254-264. PubMed ID: 29231188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis.
    Gordon SC; Wu KH; Lindor K; Bowlus CL; Rodriguez CV; Anderson H; Boscarino JA; Trudeau S; Rupp LB; Haller IV; Romanelli RJ; VanWormer JJ; Schmidt MA; Daida YG; Sahota A; Vincent J; Zhang T; Li J; Lu M;
    Am J Gastroenterol; 2020 Feb; 115(2):262-270. PubMed ID: 31985529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
    Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
    Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.